- ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS
-
The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.
- -
-
Paragraph 0762-0763
(2020/04/09)
-
- FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF
-
The present invention relates to an FGFR4 inhibitor having a structure represented by formula (I), preparation method therefor, and applications thereof. A series of compounds represented by formula (I) in the present invention have a very-strong inhibiti
- -
-
Paragraph 0128; 0129
(2019/02/28)
-
- NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
-
The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
- -
-
Page/Page column 80; 81
(2019/05/22)
-
- Intermediate compound of medicine LB80380 and preparing method and application thereof
-
The invention provides an LB80380 intermediate compound (as shown in formula I in the specification). In the LB80380 intermediate compound, R1, R2, R3 and R4 are chosen from linear chain or branched chain alkyl group, benzyl group which is replaced by one or five R5, or R5CO independently, wherein the R1, the R1, the R3 and the R4 are identical or different; R5 is chosen from hydrogen, C1-C4 alkoxy which is replaced or not replaced, C3-C7 alkenyl alkoxy, or benzyloxy- which is replaced or not replaced. The invention also provides a preparing method and an application of the compound in the formula I. When the compound in formula I is used for preparing a compound (specific chemical formula is in the specification), reaction route raw materials and intermediate materials are low in price and easy to get, cost is low, safety is good, and thus the LB80380 intermediate compound in formula I is applicable to industrial production.
- -
-
Paragraph 0194; 0195; 0196; 0197
(2017/05/12)
-
- HETEROCYCLIC COMPOUND
-
The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.
- -
-
Paragraph 0564; 0931; 0932
(2017/04/11)
-
- Heterocyclic compound
-
本發明提供一種具有CDK8/19抑制活性之雜環化合物。本發明提供一種如下式代表之化合物(其中各代號均如本文之定義)或其鹽。 The present invention provides a heterocyclic compound possessing CDK8/19 inhibitory activity. The present invention provides a compound represented by the formula wherein each symbol is as defined herein, or a salt thereof.
- -
-
Paragraph 0314
(2017/09/28)
-
- AROMATIC COMPOUND
-
Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.
- -
-
Paragraph 0863; 0864
(2016/05/19)
-
- A convenient procedure for preparation of 1-(1-aminoalkyl)-1-cyclopropanols from N-benzyl α-amino acid esters
-
The reaction of N-benzyl α-amino acid ethyl esters with ethylmagnesium bromide in the presence of a catalytic amount of titanium tetraisopropoxide leads to formation of the corresponding 1-aminoalkyl-1-cyclopropanols in high yields. Hydrogenation of the l
- Lysenko,Kulinkovich
-
p. 1238 - 1243
(2007/10/03)
-
